Next Generation News and Research

RSS

QIAGEN to acquire minority stake in Alacris Theranostics

QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.

From QIAGEN Manchester Limited 11 Jan 2011

Boston Scientific completes enrollment in Nitinol Stent System trial for treatment of iliac artery disease

Boston Scientific Corporation today announced that it has completed enrollment in the ORION clinical trial, which is designed to evaluate the Company's EPIC™ Self-Expanding Nitinol Stent System for the treatment of iliac artery disease, a form of peripheral artery disease associated with severe leg pain caused by insufficient blood flow to the muscles (claudication).

10 Jan 2011

T2 Biosystems relocates to new 20,000 sq.ft. facility in Lexington

T2 Biosystems, Inc., a company developing next-generation medical diagnostic products, today announced that it has relocated to a newly renovated 20,000 sq.ft. facility located in Lexington, MA.

10 Jan 2011

Takeda San Francisco and Pieris enter Anticalin scaffold technology collaboration

Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin(R) scaffold technology to deliver protein therapeutic candidates to Takeda, both companies announced today. The deal initially will focus on first-in-class drug discovery efforts around a predetermined Takeda target.

10 Jan 2011

Illumina announces next generation of iSelect custom genotyping products

Illumina, Inc. today announced its next generation of iSelect custom genotyping products that allow researchers to design custom arrays containing from 3,000 up to 1,000,000 markers, with the flexibility to add supplemental content to their array designs.

From Illumina, Inc. 10 Jan 2011

LabCorp to market On-Q-ity's circulating tumor cell platform

On-Q-ity, a next-generation oncology diagnostics company developing personalized and predictive tests to improve cancer therapy effectiveness, today announced a strategic alliance with Laboratory Corporation of America Holdings® (LabCorp). LabCorp will market On-Q-ity's novel and proprietary circulating tumor cell (CTC) platform to the biopharma industry to greatly accelerate and improve the cancer drug discovery and development process.

10 Jan 2011

FDA warns retailers for illegal sale of tobacco products to minors

The U.S. Food and Drug Administration today announced it is issuing its first warning letters to retailers for the illegal sale of tobacco products to minors in violation of the 2009 Family Smoking Prevention and Tobacco Control Act.

10 Jan 2011

New lab-on-a-chip technology detects protein in blood less than 30 minutes

While most blood tests require shipping a vial of blood to a laboratory for analysis and waiting several days for the results, a new device invented by a team of engineers and students at the University of Rhode Island uses just a pinprick of blood in a portable device that provides results in less than 30 minutes.

10 Jan 2011

MMRF awards $3 million under 2010 Biotech Investment Awards program

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, Inc. Since the inception of this MMRF program in 2006, $11 million has been committed to 11 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

7 Jan 2011

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

ZIOPHARM Oncology, a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon's UltraVector Technology.

7 Jan 2011

Curis announces selection of CUDC-907 as development candidate for cancer

Curis, a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company has selected CUDC-907, an orally available, synthetic small molecule inhibitor of phosphatidylinositol-3-kinase and histone deacetylase as a development candidate from its targeted cancer programs.

7 Jan 2011

GT Life Sciences and BGI complete CHO-K1 genome sequencing

GT Life Sciences, a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, and BGI, the largest genomics organization in the world, announced that they have successfully completed for the first time the sequencing of the Chinese hamster ovary genome.

6 Jan 2011

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.

6 Jan 2011

Symphogen closes €100 million stock to a group of investors

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that it closed a €100 million placement of Preferred Stock to a group of investors.

6 Jan 2011

Stereotaxis extends strategic partnership to distribute magnetic ablation catheters

Stereotaxis, Inc. announced today that the Company and its existing strategic catheter partner have extended their exclusive worldwide agreement for the distribution of existing approved magnetic ablation catheters through the end of 2015.

6 Jan 2011

Cell Biosciences introduces FluorChem M MultiFluor for detectig multicolor fluorescent Western blots

Cell Biosciences, a provider of innovative protein analysis tools to life science researchers, today announced the launch of the latest addition to their premier line of next-generation imaging products, the FluorChem M MultiFluor system.

5 Jan 2011

Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis

Carbylan BioSurgery, Inc. announced today the completion of patient enrollment in their double-blinded, multi-center COR1.0 feasibility trial to evaluate the safety and effectiveness of two products - Hydros and Hydros TA Joint Therapies - in patients with osteoarthritis of the knee. Hydros and Hydros TA are next generation viscosupplement and viscosupplement/steroid combination products.

5 Jan 2011

OrbusNeich expands patent protection for Genous endothelial progenitor cell capture technology

OrbusNeich today announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent expanding protection of the company's Genous endothelial progenitor cell (EPC) capture technology.

5 Jan 2011

Qualcomm's wireless Internet of Everything Module integrated into Telcare 3GM blood glucose meter

Qualcomm Incorporated and Telcare Incorporated today announced plans to integrate Qualcomm's wireless Internet of Everything Module (IEM) into the Telcare 3GM™ blood glucose meter being developed by Telcare. Telcare 3GM, currently in prototype phase, is designed to transfer blood glucose readings to a patient's family members or physician with each test.

5 Jan 2011

FDA approves Gore's C3 Delivery System to deploy EXCLUDER AAA Endoprosthesis

W. L. Gore & Associates (Gore) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market the GORE® C3 Delivery System to deploy the GORE® EXCLUDER® AAA Endoprosthesis as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA).

5 Jan 2011

Next Generation News and Research

QIAGEN to acquire minority stake in Alacris Theranostics

Boston Scientific completes enrollment in Nitinol Stent System trial for treatment of iliac artery disease

T2 Biosystems relocates to new 20,000 sq.ft. facility in Lexington

Takeda San Francisco and Pieris enter Anticalin scaffold technology collaboration

Illumina announces next generation of iSelect custom genotyping products

LabCorp to market On-Q-ity's circulating tumor cell platform

FDA warns retailers for illegal sale of tobacco products to minors

New lab-on-a-chip technology detects protein in blood less than 30 minutes

MMRF awards $3 million under 2010 Biotech Investment Awards program

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

Curis announces selection of CUDC-907 as development candidate for cancer

GT Life Sciences and BGI complete CHO-K1 genome sequencing

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

Symphogen closes €100 million stock to a group of investors

Stereotaxis extends strategic partnership to distribute magnetic ablation catheters

Cell Biosciences introduces FluorChem M MultiFluor for detectig multicolor fluorescent Western blots

Carbylan completes enrollment in COR1.0 feasibility trial of Hydros and Hydros TA in knee osteoarthritis

OrbusNeich expands patent protection for Genous endothelial progenitor cell capture technology

Qualcomm's wireless Internet of Everything Module integrated into Telcare 3GM blood glucose meter

FDA approves Gore's C3 Delivery System to deploy EXCLUDER AAA Endoprosthesis

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News